News

ADC Therapeutics Reveals Exciting Results for ZYNLONTA in Trials

ADC Therapeutics Reveals Exciting Results for ZYNLONTA in Trials

Exciting Insights on ZYNLONTA's Efficacy in Recent Trials

ADC Therapeutics SA (NYSE: ADCT) has recently unveiled significant findings from its LOTIS-7 Phase 1b clinical trial that showcases the combination of ZYNLONTA® with the bispecific antibody, glofitamab (COLUMVI®). This study is pivotal for patients suffering from relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). These updated results indicate encouraging overall response rates and a generally well-tolerated safety profile among participants.

Outstanding Results from LOTIS-7 Trial

The trial's findings are based on the analysis of 49 patients, all of whom had a minimum of six months of follow-up post-treatment. The combination therapy resulted in a remarkable objective response rate (ORR) of 89.8%, with a complete response (CR) rate of 77.6%. These figures are indicative of the potential effectiveness of ZYNLONTA in treating challenging cancer cases.

The Positive Impact on Patients

The fact that 33 out of the 38 patients who achieved a complete response maintained their CR status underscores the treatment's promise. Among the relapsed patient group, the combination reached an astonishing 100% ORR, while 91.7% of this segment achieved complete responses. In the primary refractory patient population, the therapy delivered an ORR of 80% and a CR rate of 64%, demonstrating a solid therapeutic impact across diverse patient backgrounds.

A Comprehensive Safety Profile

Moreover, the combination of ZYNLONTA and glofitamab continues to exhibit a manageable safety profile, which is crucial for patient wellbeing during treatment. While there were instances of treatment-emergent adverse events (TEAEs) like neutropenia and anemia reported, the majority were low grade. The most severe side effects witnessed were grade 5 adverse events, occurring in only a small fraction of patients. Notably, cytokine release syndrome (CRS) was observed in 36.7% of the total patient group, mostly of low grade, adding to the evidence of the regimen's tolerability.

Future Outlook for LOTIS-7

ADC Therapeutics is moving ahead with the LOTIS-7 trial, aiming to enroll around 100 patients at the specified dose. They plan to present full results at upcoming medical meetings and anticipate publishing these findings by the year's end. This suggests an ongoing commitment to advancing treatment for DLBCL and a strategic plan to maximize the trial's impact.

About ZYNLONTA®

ZYNLONTA® is an innovative CD19-directed antibody-drug conjugate (ADC) designed specifically to target cancer cells. Upon binding to these cells, ZYNLONTA is internalized, where its potent payload effectively interferes with DNA function, ultimately leading to cell death. The U.S. FDA has granted it accelerated approval for usage in patients with r/r large B-cell lymphoma after multiple rounds of treatment, marking a significant advancement in therapy options.

Comprehensive Treatment Approach

In addition to its use in r/r DLBCL, ZYNLONTA is also being tested in a variety of combination strategies across other B-cell malignancies and various lines of therapy. This comprehensive approach highlights ADC Therapeutics' commitment to broadening therapeutic options for patients with unsupported conditions.

A Glimpse into ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) stands out as a pioneering entity in the realm of antibody-drug conjugates, transforming treatment pathways for patients with complex biomedical needs. Their focus on ZYNLONTA along with other leading-edge therapies positions them at the forefront of cancer treatment innovation, making them a key player in the global pharmaceutical landscape.

Frequently Asked Questions

What were the key findings from the LOTIS-7 trial?

The LOTIS-7 trial results indicated an ORR of 89.8% and a CR rate of 77.6% for patients treated with ZYNLONTA in combination with glofitamab.

How many patients were involved in the LOTIS-7 trial?

A total of 49 efficacy-evaluable patients participated in the trial, all of whom had at least six months of follow-up.

What are the safety observations from the study?

The safety profile of the combination was found to be manageable, with the most common treatment-emergent adverse events being low grade.

What plans does ADC Therapeutics have for future research?

ADC Therapeutics aims to complete enrollment for the LOTIS-7 trial by 2026, with intentions to share full results at medical conferences and in publications.

What is the significance of ZYNLONTA in the treatment landscape?

ZYNLONTA represents a novel approach to targeting CD19 in solid tumors, providing hope for patients after multiple lines of therapy.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 59

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Mars Moves on Cash Tender Offers for Seniors' Notes

Updated Category News Views 104

A Strategic Financial Maneuver or a Casual Gambit? Okay, what’s Mars up to now, you ask? Here we go with this. The behemoth behind some of your favorite snacks and pet indulgences is making waves—not with candy, but with cash. Mars, Incorporated is rolling out tender offers to buy back a substantial chunk of its Senior Notes for $2 billion in cold, hard cash. When a...

Continue Reading
VIO Med Spa’s Black Friday Event: Aesthetic Savings

Updated Category News Views 123

Kicking Off the Holiday Season with a Glow Just when you think the holiday hustle can't get busier, VIO Med Spa is opening the gates of rejuvenation just in time to add yourself to that epic list. Starting November 16, VIO launches its Black Friday extravaganza—a deal-laden kick-off that means smooth skin and sharper looks are up for grabs. Member Benefits and Public...

Continue Reading
MoneyGram and Solflare Boost Crypto Cash-Out Options

Updated Category News Views 116

Crypto Meets Cash: A New Partnership in Money Movement Here's something to chew over your morning joe: MoneyGram's stepping up its game in the crypto world. They're pairing up with Solflare to let folks convert their USDC into hard cash across 170 countries and territories—no fees until New Year's Eve. It's like crypto's getting a passport to the physical world and not...

Continue Reading
Daymond John's Four-Center Bet on Longevity Game

Updated Category News Views 66

A Shark's Dive into Longevity Here you go—Daymond John, the face of FUBU and a household name from Shark Tank, is not just talking about living longer; he's putting his wallet where his words are. John is jumping into the longevity game with both feet, joining Ultimate Longevity Center's (ULC) latest venture. We're talking about four new centers across California,...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 142

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
Sinch Appoints Jonas Dahlberg as New CEO: A Strategic Move

Updated Category News Views 47

A Change at the Helm: Dahlberg Takes Charge Here we go, folks—Sinch, that global powerhouse in customer communications, just got itself a new captain. Jonas Dahlberg is now officially the CEO, after warming the acting CEO seat since June. This ain't your ordinary office shuffle. It's a calculated chess move in the high-stakes tech world. Dahlberg's Path to the Top This...

Continue Reading
Trades Workforce Shortage Costs Wallop U.S. Economy

Updated Category News Views 113

The Forgotten Backbone of America Don't sleep on this: America's got itself a trade worker crisis, and it's not just a numerical hiccup. We’re down nearly 1.9 million skilled trades workers, and that's a gut punch to the economy—a hefty $1.2 billion a day in GDP loss. These are the folks who keep the wheels greased, the lights on, and the goods flowing. Without them,...

Continue Reading
Alliance for Women in Media Champions Change in 2026

Updated Category News Views 76

A Celebration of Trailblazing Women in Media If there's one thing I've learned about strong leadership, it's that you can't fake authenticity. Today, we're tipping our hats to some genuine trailblazers. The Alliance for Women in Media (AWM) held its annual Gracies Leadership Awards, celebrating the achievements and vision of seven remarkable women. Honoring the...

Continue Reading
Webull Faces FINRA Fine and Legal Battle Ahead

Updated Category News Views 100

Webull's Compliance Headache Webull’s been knocked around again. This time, the Financial Industry Regulatory Authority (FINRA) slapped it with a hefty $4.2 million fine. Talk about a hit to the wallet! It all boils down to them failing to roll out some basic anti-money laundering (AML) and other crucial compliance programs. This is no small oversight, and it's got...

Continue Reading

Top 5 Most Recently Viewed Articles

South32 Secures Key Environmental Approval for Worsley Mine

Updated Category News Views 283

South32's Worsley Mine Project Receives Environmental Approval Perth-based South32 (ASX / LSE / JSE: S32; OTC: SOUHY), an Australian leader in mining and metals, has recently obtained essential state environmental approval for its Worsley Mine Development Project. This significant milestone brings the company a step closer to accessing necessary bauxite resources, vital...

Continue Reading
Tesla's Future Beyond EVs: The Rise of AI, Robotics, and Robotaxis

Updated Category News Views 471

Tesla's Future Beyond EVs: The Rise of AI, Robotics, and Robotaxis Tesla Inc. (NASDAQ:TSLA) is trading near $418.02, showcasing a remarkable market cap of $1.31 trillion and a P/E ratio of 279.5. This impressive valuation not only underscores the innovation premium associated with Tesla but also reflects the intense valuation pressures it faces. The company has...

Continue Reading
Smartkem Showcases Innovative Display Technology at TechBlick

Updated Category News Views 44

Smartkem Set to Exhibit at TechBlick: A Spotlight on Future Electronics Smartkem, Inc. (NASDAQ: SMTK), a leader in transformative display technologies, is gearing up to showcase its innovative offerings at an upcoming global conference centered on electronics. This event, known as TechBlick: The Future of Electronics Reshaped, will take place at the Estrel Berlin Hotel...

Continue Reading
American Rebel Light Beer: Expanding Horizons in Iowa

Updated Category News Views 170

American Rebel Light Beer Expands Distribution in Iowa American Rebel Light to be served at Knoxville Raceway and the Dingus Lounge Nashville, TN — American Rebel Holdings, Inc. (NASDAQ: AREB) proudly announces its strategic expansion into Iowa through a partnership with Mahaska Bottling Company. This important move marks a significant milestone in the Company's broader...

Continue Reading
Boys & Girls Clubs Ignite Hope with Woodlands Impact Center

Updated Category News Views 195

Boys & Girls Clubs of the Northwest Suburbs Renovate New Facility The Woodlands Impact Center is poised to play a vital role in empowering local youth by providing essential services and programs. This facility aims to support 550 students, offering after-school, summer, and daytime activities that will enrich their educational and social experiences. A Transformative...

Continue Reading